Georgia is currently home to 1911 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Postprandial Urolithin Patterns Following Pecan Consumption
NCT06140602
Recruiting
Pecan-enriched diets have been linked to improved cardiovascular health, including postprandial blood lipids and microvascular reactivity in older adults. This has led to recommendations to increase regular pecan consumption, however there is no consistent plasma measure of pecan intake. Traditionally, plasma tocopherols have been used, although they reach peak concentrations in plasma around 6-8 hours post pecan consumption, leading to high variability at 24 hours. Therefore, a more reliable bi... Read More
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
11/20/2023
Locations: Human Nutrition Lab, Athens, Georgia
Conditions: Change in Plasma Urolithins and Vitamin E
Register for Updates
Smart Textile Sensor System for Health Monitoring
NCT05473702
Recruiting
The present study will investigate a set of biomedical sensors with a wireless data communication system and evaluate the sensors' recording quality. The sensors and wearable wireless system have been approved by Food and Drug Administration (FDA) for recording Electrocardiography (ECG), Trans Thoracic Impedance (TTI), Heart Sounds and Acitigraphy. The sensors and wireless system will be used along with conventional sensor systems (as intended to be used).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/07/2023
Locations: Clincept, Atlanta, Georgia
Conditions: Heart Disease Chronic, Pulmonary Disease, Chronic Obstructive, Blood Pressure, Heart Rhythm Disorder
Register for Updates
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
NCT05082519
Recruiting
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even those who start chemotherapy at a healthy weight. This study is being done to find out if caloric restriction achieved by a personalized nutritional menu and exercise plan during routine chemotherapy... Read More
Gender:
ALL
Ages:
Between 10 years and 25 years
Trial Updated:
10/25/2023
Locations: Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia
Conditions: B-cell Acute Lymphoblastic Leukemia, Obesity
Register for Updates
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab
NCT05199285
Recruiting
This phase II trial tests whether nivolumab and ipilimumab works to shrink tumors in patients with liver cancer that has spread to nearby tissue or lymph nodes (locally advanced), has spread to other places in the body (metastatic), or cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Nivolumab and ipilim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/13/2023
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Register for Updates
Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome
NCT05875948
Recruiting
This study aims to evaluate the safety, tolerability and efficacy of R2R01 combined with terlipressin as compared to terlipressin alone in the treatment of patients with HRS-AKI
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/29/2023
Locations: Piedmont Healthcare, Inc, Atlanta, Georgia
Conditions: Hepatorenal Syndrome, Acute Kidney Injury
Register for Updates
Post-Approval Study of the TREO Abdominal Stent-Graft System
NCT04697784
Recruiting
The purpose of this study is to determine the long-term performance of the TREO Abdominal Stent-Graft as a treatment for patients with Infrarenal Abdominal Aortic Aneurysms or Aorto-iliac Aneurysms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/27/2023
Locations: Piedmont Heart Institute, Atlanta, Georgia
Conditions: Abdominal Aortic Aneurysm
Register for Updates
A Randomized, Controlled Trial Comparing the Use of a Biodegradable Temporizing Matrix to Cadaver Skin in the Reconstruction of Hidradenitis Suppurativa Excisions
NCT05477225
Recruiting
This will be a prospective, interventional, single-center, randomized, controlled, comparative study comparing a total of 10 patients treated with BTM and SOC in wounds diagnosed with Hidradenitis suppurativa (5 in each group).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2023
Locations: Joseph M. Still Research Foundation, Augusta, Georgia
Conditions: Hidradenitis Suppurativa
Register for Updates
A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis
NCT04956744
Recruiting
This is a Phase 1 study of IMS001, given as a single dose to subjects with Multiple Sclerosis who experience inadequate response and/or intolerability to disease modifying treatments. IMS001 is a human embryonic cell derived (hESC) mesenchymal stem cell (MSC). MSCs have the potential to modulate disease course.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
09/26/2023
Locations: Shepherd Center, Atlanta, Georgia
Conditions: Multiple Sclerosis
Register for Updates
Evaluate the SENSE Device's Ability to Monitor and Detect Intracranial Hemorrhage
NCT04642443
Recruiting
This study is a two-stage, pivotal, prospective, non-randomized, multi-center, within patient comparison of the SENSE device and the standard diagnostic test, head CT scan in patients with a diagnosis of primary spontaneous ICH or traumatic intracranial bleeding for the detection and monitoring of intracranial hemorrhages.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
09/25/2023
Locations: Grady, Atlanta, Georgia
Conditions: Intracranial Hemorrhages, Traumatic Brain Injury
Register for Updates
OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps
NCT03747458
Recruiting
This is a 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day (BID) in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase. The total planned number of subjects is approximately 120 adolescents (12-17 years of age) who will be randomly assigned to receive 1 of 2 study treatments using a 2:1 ratio (OPN-375 186 μg: Placebo). For the PK sub-study, up to 14 subjec... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
09/22/2023
Locations: Children's Healthcare of Atlanta, Atlanta, Georgia
Conditions: Bilateral Nasal Polyposis
Register for Updates
A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
NCT04786574
Recruiting
The primary objective of this study is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney disease (ARPKD)
Gender:
ALL
Ages:
Between 28 days and 12 weeks
Trial Updated:
09/14/2023
Locations: Emory University, Atlanta, Georgia
Conditions: Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Register for Updates
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
NCT03037164
Recruiting
Stage A: To evaluate the safety and efficacy of red blood cells (RBCs) prepared with the INTERCEPT Blood System for Red Blood Cells Pathogen Reduction Treatment (PRT) in comparison to conventional RBCs in patients who require RBC transfusion support. Stage B: To provide early access to the INTERCEPT pathogen reduction system for RBC in regions where a substantial proportion of the population has been infected or is at risk of a transfusion-transmissible infection. The objectives and design of... Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
09/11/2023
Locations: Grady Health System, Atlanta, Georgia
Conditions: Anemia
Register for Updates